| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1054500 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | organism-based format | GSK Malaria Screening | ||
| 2. | ALA1054501 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | organism-based format | GSK Malaria Screening | ||
| 3. | ALA1054502 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | organism-based format | GSK Malaria Screening | ||
| 4. | ALA1054503 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | Plasmodium falciparum | 13,467 | organism-based format | GSK Malaria Screening | ||
| 5. | ALA1054504 | F | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | Homo sapiens | 13,467 | cell-based format | GSK Malaria Screening | ||
| 6. | ALA1054505 | F | GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested | 13,467 | assay format | GSK Malaria Screening | |||
| 7. | ALA1040691 | F | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | organism-based format | Novartis Malaria Screening | ||
| 8. | ALA1040692 | F | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | organism-based format | Novartis Malaria Screening | ||
| 9. | ALA1040693 | T | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | Homo sapiens | 5,614 | cell-based format | Novartis Malaria Screening | ||
| 10. | ALA1040694 | F | NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. | 5,614 | assay format | Novartis Malaria Screening | |||
| 11. | ALA1614166 | B | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | 34,209 | single protein format | PubChem BioAssays | |||
| 12. | ALA1614234 | F | PUBCHEM_BIOASSAY: qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium. (Class of assay: confirmatory) [Related pubchem assays: 901 ] | Rattus norvegicus | 11,394 | assay format | PubChem BioAssays | ||
| 13. | ALA1614236 | F | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | Influenza A virus (A/WSN/1933(H1N1)) | 32,268 | assay format | PubChem BioAssays | ||
| 14. | ALA1614249 | B | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | Equus caballus | 42,059 | single protein format | PubChem BioAssays | ||
| 15. | ALA1614459 | F | PUBCHEM_BIOASSAY: qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells. (Class of assay: confirmatory) | Drosophila | 88,408 | assay format | PubChem BioAssays | ||
| 16. | ALA1613791 | F | PUBCHEM_BIOASSAY: A counter screen for small molecule screen for inhibitors of the PhoP region in Salmonella typhi. (Class of assay: confirmatory) [Related pubchem assays: 1850, 1864, 2252, 1985 ] | 1,121 | assay format | PubChem BioAssays | |||
| 17. | ALA1614195 | F | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1476 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent))] | Trypanosoma cruzi | 1,957 | assay format | PubChem BioAssays | ||
| 18. | ALA1614257 | F | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | Homo sapiens | 37,649 | assay format | PubChem BioAssays | ||
| 19. | ALA1614275 | F | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia. (Class of assay: confirmatory) [Related pubchem assays: 2472, 2464 ] | Giardia intestinalis | 14,723 | assay format | PubChem BioAssays | ||
| 20. | ALA1614280 | F | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of L3MBTL1. (Class of assay: confirmatory) [Related pubchem assays: 485292 (Probe Development Summary for Inhibitors of L3MBTL1)] | Homo sapiens | 13,811 | assay format | PubChem BioAssays |
The page will load shortly, Thanks for your patience!